Miragen Therapeutics is a clinical-stage biopharmaceutical company discovering and developing proprietary RNA-targeted therapies with a focus on microRNAs and their role in diseases. Co.'s product candidates include: cobomarsen, which is for the treatment of patients with certain cancers that have elevated microRNA-155, including cutaneous T-cell lymphoma, and adult T-cell leukemia/lymphoma; remlarsen, which is for the potential treatment of patients with pathological fibrosis, including idiopathic pulmonary fibrosis; and MRG-110, which is for the treatment of heart failure, wound healing, and other ischemic disease. We show 20 historical shares outstanding datapoints in our MGEN shares outstanding history coverage, used to compute MGEN market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing MGEN market cap history over the course of time is important for investors
interested in comparing MGEN's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of MGEN versus a peer is one thing; comparing
MGEN market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like MGEN can fluctuate over the course of history.
With this page we aim to empower investors researching MGEN by allowing them to research the MGEN market cap history. |
Free MGEN Email Alerts:
Video: The Importance of Market Cap
